The annual rate of consumജer inflation in the U.S. is expected to rise for the second straight month, and ADRs of Chinese electric vehicle makers fell after the European Union opened an investigation into price subsidies. Here’s what investors need to know today.

1. Headline Inflati�ღ�on Projected to Rise for Second Straight Month

Headline inflation as tracked by the Consumer Price Index (CPI) is expected to have climbed to an annual rate of 3.6% in August, up from the 3.2% it registered in July, which would mark the second straight month that it has increased, when the Labor Department releases its latest inflation report at 8:30 a.m. ET. The CPI is forecasted to have climbed 0.6% month-over-month in August, up from 0.2% in July. The core CPI, which excludes food and energy costs, is expected to have slowed to an annual rate of 4.3% in August, down from 4.7% in July.

2. ADRs of Chinese EV Makers Dec𒁃line as EU Open🌱s Investigation into Subsidies

澳洲幸运5官方开奖ꦦ结果体彩网:American depositary receipts (ADRs) of Chinese electric vehicle makers fell in pre-market trading after the European Commission said it would launch an investigation into Chinese EVs and whether government subsidies are keeping their prices artificially low. ADRs of Xpeng (XPEV) dropped 3.1%, and Nio (NIO) declined 2.7%, while Tesla (TSLA) shares gained 0.4% amid optimism it could benefit from EU restrictions on Chinese EVs.

3. BP Shares Rebound♍ After Falling Following CEO Departure

ADRs of 澳洲幸运5官方开奖结果体彩网:oil giant BP (BP) rose 2% in pre-market trading after falling 1.3% yesterday following the news that CEO Bernard Looney resigned following an investigation of personal relationships with colleagues which he had not disclosed. Some investors had been frustrated with Looney’s focus on green energy, believing it responsible for BP’s lower valuation compared with Exxon Mobil (XOM) and Chevron (CVX).

4. 𝓰Rocket Pharmaceuticals Shares Surge as FDA Approves Drug Tr🍃ial

Rocket Pharmaceuticals (RCKT) shares jumped 19% in pre-market trading after the company said it reached alignment with the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration for its Phase 2 trial for the treatment of Danon disease. The trial could help accelerate the FDA approval of Rocket's treatment.

5. Ford Shares Rise on Plans 🌸to Boost Production o🐻f Hybrid F-150

Shares of Ford (F) rose nearly 2% in pre-market trading after it said it plans to double production of the hybrid version of its F-150 pickup truck in response to slower-than-expected sales of its all-electric vehicles. Ford said it expects to increase sales of the V-6 hybrid model by 20% in 2024.